# Real-world outcomes of lurasidone augmentation for treatment-resistant bipolar depression: a retrospective observational analysis

## TL;DR

This study examines how adding lurasidone helps patients with treatment-resistant bipolar depression, finding some improvement but limited remission.

## Contribution

The study provides real-world evidence on lurasidone's effectiveness and tolerability as an adjunctive treatment for treatment-resistant bipolar depression.

## Key findings

- Significant reductions in depressive and anxiety symptoms were observed in patients receiving lurasidone.
- Clinical response was achieved in 33.3% of participants, but remission occurred in only 3.3%.
- Adverse events were reported in 68.3% of patients, but were mostly mild to moderate.

## Abstract

Treatment-resistant bipolar depression (TRBD) is a major challenge in psychiatric practice, leading to marked impairment in functioning and quality of life, and increased healthcare utilization. Despite its clinical relevance, consensus on diagnostic criteria and evidence-based therapeutic strategies remains limited. Within the framework of personalized medicine, identifying effective and well-tolerated options for this heterogeneous population is important. This study evaluates the short-term effectiveness and tolerability of lurasidone as an adjunctive treatment in TRBD, with attention to its potential role in tailoring interventions to individual clinical profiles.

This four-week, retrospective, multicentre observational study included patients with TRBD receiving lurasidone in augmentation to ongoing pharmacological treatment. Dosages were adjusted according to clinical judgement. Symptom severity was assessed with the 17-item Hamilton Depression Rating Scale (HAM-D), Young Mania Rating Scale (YMRS), and Hamilton Anxiety Rating Scale (HAM-A). Changes from baseline to endpoint were analyzed with repeated measures ANOVA; missing data were managed with the Last Observation Carried Forward (LOCF) method.

Sixty patients were enrolled. The mean final lurasidone dose was 51.2 mg/day. Significant improvements were observed across all scales, with consistent reductions in depressive and anxiety symptoms. Clinical response was achieved in 33.3% of participants, while remission occurred in 3.3%. Adverse events were reported by 68.3% of completers, all mild to moderate.

Lurasidone appears to be an effective and generally well-tolerated adjunctive option for TRBD. However, remission rates remained low, underscoring the need for further research. In this perspective, lurasidone may contribute to more individualized treatment strategies for difficult-to-treat patients, although confirmatory studies are required to better define its role within precision psychiatry.